Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

MAB8702

Sigma-Aldrich

Anti-Dengue Virus Type II Antibody, clone 3H5-1

clone 3H5-1, Chemicon®, from mouse

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41

Origine biologica

mouse

Livello qualitativo

Forma dell’anticorpo

purified immunoglobulin

Clone

3H5-1, monoclonal

Reattività contro le specie

human

Produttore/marchio commerciale

Chemicon®

tecniche

immunofluorescence: suitable
inhibition assay: suitable (hemagglutination)

Isotipo

IgG1

Condizioni di spedizione

wet ice

Descrizione generale

Dengue fever is an acute, mosquito-transmitted viral disease characterized by fever, headache, arthralgia (severe retro-orbital pain), myalgia, rash, nausea, and vomiting. Infections are caused by any of the four closely related, but antigenically distinct virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). Infection with one of these serotypes does not provide cross-protective immunity, so persons living in a dengue-endemic area can have four dengue infections during their lifetimes. Dengue is primarily an urban disease of the tropics, and the viruses that cause it are maintained in a cycle that involves humans and Aedes aegypti, a domestic, day-biting mosquito that prefers to feed on humans. Although most dengue infections result in relatively mild illness, some can produce Dengue Hemorrhagic Fever (DHF) or dengue shock syndrome, with children being particularly at risk. Although epidemic outbreaks have been reported since 1779, the incidence has been increasing, with global, multiple serotype pandemics intensifying within the last 15 years. There is no specific antiviral therapy for dengue, but for both classical dengue and dengue hemorrhagic fever, symptomatic and supportive measures are effective. Important risk factors for DHF include the strain and serotype of the virus involved, as well as the age, immune status, and genetic predisposition of the patient.

Specificità

Reacts with the Dengue type 2 virus.

Immunogeno

Dengue type 2 antigen (New Guinea C).

Applicazioni

Recommended for use in an immunofluorescent assay. Also suitable for use in hemagglutination-inhibition tests and plaque-reduction assays.

IFA: 1:200-1:400.

Dilute with buffer pH 7.5-8.0 to desired working volumes. For extensive dilution, protein containing or other stabilizing medium should be used.

Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
This Anti-Dengue Virus Type II Antibody, clone 3H5-1 is validated for use in HI, IF for the detection of Dengue Virus Type II.

Stato fisico

Format: Purified
Protein G Purified
Protein G Purified immunoglobulin. Liquid in 0.02 M PB, 0.25 M NaCl, pH = 7.6 with 0.1% Na Azide as a preservative

Stoccaggio e stabilità

Maintain at 2°C to 8°C in undiluted aliquots for up to 12 months after date of receipt.

Risultati analitici

Control
Dengue positive patient sample

Altre note

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Note legali

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Codice della classe di stoccaggio

10 - Combustible liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Leticia Franco et al.
PLoS neglected tropical diseases, 5(8), e1251-e1251 (2011-08-11)
Dengue virus (DENV) circulates in human and sylvatic cycles. Sylvatic strains are both ecologically and evolutionarily distinct from endemic viruses. Although sylvatic dengue cycles occur in West African countries and Malaysia, only a few cases of mild human disease caused
Sialic acid expression in the mosquito Aedes aegypti and its possible role in dengue virus-vector interactions.
Cime-Castillo, J; Delannoy, P; Mendoza-Hernandez, G; Monroy-Martinez, V; Harduin-Lepers et al.
BioMed Research International null
Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking.
van der Schaar, HM; Rust, MJ; Waarts, BL; van der Ende-Metselaar, H; Kuhn, RJ; Wilschut et al.
Journal of virology null
Zhi-Shan Zhang et al.
Molecular medicine reports, 11(2), 1009-1016 (2014-11-06)
There is currently no effective vaccine to prevent dengue infection, despite the existence of multiple studies on potential methods of immunization. The aim of the present study was to explore the effect of DNA and/or recombinant protein on levels of
Hilde M van der Schaar et al.
PLoS pathogens, 4(12), e1000244-e1000244 (2008-12-20)
Dengue virus (DENV) is an enveloped RNA virus that causes the most common arthropod-borne infection worldwide. The mechanism by which DENV infects the host cell remains unclear. In this work, we used live-cell imaging and single-virus tracking to investigate the

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.